Left ventricular hypertrophy does not prevent heart failure in experimental hypertension

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Hypertension-induced left ventricular hypertrophy (LVH) is paradoxically linked to increased cardiovascular risk.
• The role of LVH in preventing heart failure (HF) despite its association with adverse outcomes requires further investigation.

Purpose of the Study:

• To determine if antihypertensive medications inhibit LVH.
• To assess the impact of these treatments on beta-adrenergic response.
• To evaluate effects on myocardial oxidative metabolism.

Main Methods:

• Spontaneously hypertensive rats (SHR) received losartan, hydralazine, rosuvastatin, or carvedilol.
• Cardiac function was assessed using the Langendorff system with isoproterenol stimulation.
• Left ventricular weight and expression of key proteins (thioredoxin 1, peroxyredoxin 2, glutaredoxin 3, caspase-3, BNP) were measured.

Main Results:

• Antihypertensive treatments generally reduced blood pressure, though some groups showed elevated levels.
• Left ventricular weight normalized by body weight was increased in SHR and rosuvastatin groups.
• Expression of thioredoxin 1, peroxyredoxin 2, and glutaredoxin 3 was elevated across multiple treatment groups.

Conclusions:

• LVH may not be essential for preventing HF, contrary to traditional beliefs.
• Increased thioredoxin expression induced by antihypertensive therapy may contribute to HF protection.